Vividion Therapeutics, a biopharmaceutical company, has made a significant discovery in the development of novel cancer and immune disorder treatments.
Vividion’s chemoproteomic platform enabled the discovery of a covalent allosteric inhibitor of WRN helicase, known as VVD-133214 (RO7589831). WRN is a promising target for cancers with microsatellite instability.
The publication of the discovery in Nature highlights Vividion’s approach to identifying and developing new therapeutics. The company’s platform has allowed it to target traditionally undruggable targets by identifying functional pockets on proteins and compounds that specifically interact with them.
Roche, Vividion’s partner, is currently investigating VVD-133214 in a Phase 1 clinical trial. The success of this drug candidate demonstrates the potential of Vividion’s chemoproteomics platform to advance new treatments for difficult-to-treat diseases.
Vividion is a subsidiary of Bayer AG and has leveraged its platform to identify numerous previously unknown functional pockets on protein targets. The company’s proprietary covalent chemistry library contains compounds that selectively interact with these pockets, enabling the development of a diverse pipeline of small molecule therapeutics for a wide range of diseases.
